



Pharmacy Update

January 14, 2020

COVID-19 At-Home Over-The-Counter Test Kit Imperative

For Commercial (non-Medicaid) Plan Members at No Cost

On January 10, 2022, the Biden-Harris Administration announced insurance companies and group health plans would be required to cover the cost of at-home over-the-counter (OTC) COVID-19 tests. This means people with private health coverage can get tests at no cost, effective January 15, 2022 (<https://www.cms.gov/newsroom/press-releases/biden-harris-administration-requires-insurance-companies-and-group-health-plans-cover-cost-home>).

In order to facilitate the dispensing of COVID-19 OTC test kits for Eligible Persons whose Plan Sponsors elect to cover the kits through the pharmacy benefit with **no cost-share to the Eligible Person**, CVS Caremark® will adjudicate COVID-19 OTC test kits through the pharmacy benefit effective January 15, 2022. For applicable CVS Caremark Plan Sponsors, pharmacies may be reimbursed at the pharmacy's submitted **usual and customary** charge for paid claims. Pharmacies should be aware that a lower-of-logic comparison to **Gross Amount Due** also will apply.

Providers must submit their usual and customary charge in NCPDP field # 426-DQ. The usual and customary charge must reflect the lowest price Provider would charge any customer for the same COVID-19 OTC test kit on the same date of service. For the avoidance of doubt, a Provider's usual and customary charge must be the same price as offered to customers who are purchasing a COVID-19 OTC test kit without involvement of the pharmacy department or use of their insurance benefits.

Note: CVS Caremark's adjudication logic is available on January 15, 2022, to conform to the Biden-Harris administration imperative. CVS Caremark will follow up with formal contracting through the normal contracting channels in the near future.

This update applies to:
All Network Pharmacies

Line of Business:
Commercial, Exchange
(Not applicable to
Medicare Part D PDP's)

Pharmacy Inquiries:
If you have questions, call the Pharmacy Help Desk number provided in the claim response or **1-800-364-6331** if one is not provided.

Payer Sheets:
For additional claim processing information, refer to the CVS Caremark Payer Sheets at www.caremark.com/pharminfo > NCPDP Payer Sheets.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711 and/or fax the opt-out request to 401-652-0893, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvshealth.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt. An opt out request will not opt you out of purely informational, non-advertisements, Caremark pharmacy communications such as new implementation notices, formulary changes, point-of sale issues, network enrollment forms, and amendments to the Provider Manual.

This communication and any attachments may contain confidential information. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents, is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual, and as such is Caremark Confidential Information that must be protected by the Provider and used only as described in the Provider Manual.



Processing Information

Additional requirements for claims processing and dispensing of COVID-19 OTC test kits are:

- An order from a health care provider is not required for Eligible Persons to access test kits; if Eligible Persons do not present a prescription for an COVID-19 OTC test kit, the pharmacy should enter the dispensing pharmacist's NPI as the Prescriber ID on the claim.
- There is a maximum limit of 8 tests per Eligible Person per 30 days, and there are no quantity limits when prescribed by a healthcare provider.
- Of those COVID-19 OTC test kits listed in the drug compendia, the following are known at this time to be **excluded** from the benefit:
 - Pixel by LabCorp™
 - MyLAB Box™
 - Ellume™

Note: If an excluded kit is submitted, the pharmacy may receive the following or similar reject messages: Reject 70: <<NOT COVERED UNDER PHARMACY BENEFIT>> or <<NDC NOT COVERED PLAN EXCLUSION>>.

- If the plan is not covering COVID-19 OTC test kits at this time as part of its pharmacy benefit, your pharmacy may receive the following or similar reject: Reject 70: << NOT COVERED UNDER PHARMACY BENEFIT>> or <<OTC NOT COVERED>>.
- If your pharmacy receives a "Pharmacy not contracted" or "Non-participating pharmacy" reject, the following override code may be utilized: Submission Clarification Code (SCC) 12 in NCPDP Field# 420-DK.

IMPORTANT INFORMATION

Government-provided COVID-19 test kits acquired by pharmacies to distribute to Eligible Persons for free are not part of this reimbursement program; do not submit claims to CVS Caremark for reimbursement for these government-provided test kits.

Testing conducted to screen for general workplace health and safety (such as employee "return to work" programs), for public health surveillance for SARS-CoV-2, or for any other purpose not primarily intended for individualized diagnosis or treatment of COVID-19 or another health condition is beyond the scope of section 6001 of the FFCRA (Families First Coronavirus Response Act).

This document contains references to brand-name products that are trademarks or registered trademarks of medical diagnostic companies not owned by CVS Caremark.

This communication and any attachments may contain confidential information. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution, or copying of it or its contents, is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. This communication is a Caremark Document within the meaning of the Provider Manual, and as such is Caremark Confidential Information that must be protected by the Provider and used only as described in the Provider Manual.